Myriad Genetics secured FDA approval for its MyChoice CDx as the companion diagnostic for GSK's PARP inhibitor Zejula, validating the test's genomic instability scoring and BRCA assessment for patient selection in advanced ovarian cancer. The clearance affirms Myriad's position in HRD testing and supports precision use of PARP therapy. Separately, CMS granted coverage for NeoGenomics' PanTracer LBx solid tumor blood test, expanding reimbursement for blood‑based comprehensive genomic profiling to inform therapy selection and trial enrollment in advanced solid tumors. Together the actions reflect active regulatory and payer movement to integrate genomic tools into treatment pathways.